Lisa Wyman
About Lisa Wyman
Lisa Wyman is Chief Technical & Quality Officer (CTQO) at Scholar Rock, appointed effective January 27, 2025; she is 47 years old as of March 31, 2025, and holds a B.S. in Biology (Ithaca College) and an M.S. in Engineering Management (Tufts University) . She previously led technical operations at Generate:Biomedicines and Acceleron Pharma, including executive team roles and enterprise transformation efforts tied to commercial readiness (supporting sotatercept/WINREVAIR and Reblozyl) and Acceleron’s sale to Merck for over $11B in 2021 . Company performance context: SRRK’s TSR (fixed $100 investment basis) rose to $173.99 in 2024 vs $75.68 in 2023 and $36.43 in 2022, while the company reported no revenue in 2023–2024 and negative net income in those years .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Generate:Biomedicines | Chief Technical Operations Officer; Executive Leadership Team member | Sep 2022 – Jan 2025 | Built out global technical operations (CMC, technical development, quality, supply); supported portfolio scaling |
| Acceleron Pharma Inc. | SVP Technical Operations & Quality; Executive Committee member | Jan 2019 – Sep 2022 (Exec Committee Jul 2020 – Nov 2021) | Led CMC strategy for accelerated development of sotatercept (WINREVAIR) and supported Reblozyl launch; contributed to transformation to fully integrated biotech culminating in sale to Merck (~$11B) |
| Mersana Therapeutics, Inc. | Leadership positions | Not disclosed | Roles of increasing responsibility in technical/quality operations |
| Shire plc | Leadership positions | Not disclosed | Leadership roles in technical/quality domains |
| Boston Scientific Corporation | Leadership positions | Not disclosed | Leadership roles in technical/quality domains |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| PepGen, Inc. | Director | Current as of Apr 2025 | External board role contributing technical/operations perspective |
Fixed Compensation
- Not disclosed for Lisa Wyman in the 2025 DEF 14A or related 8-K filings reviewed .
- Company program context (2024 NEOs): non-CEO target bonus % set at 40% for CMO/CSO; CEO at 60%, with actual bonuses based on corporate goals (100% for CEO; 85% corporate/15% individual for other NEOs) .
Performance Compensation
- Not disclosed for Lisa Wyman (no individual metrics/targets/payouts provided) .
- Company equity incentive approach (context): time-based stock options and RSUs for executives; the committee may evaluate introducing performance-based equity in future .
Equity Ownership & Alignment
- Total beneficial ownership for Lisa Wyman is not disclosed in the 2025 proxy’s beneficial ownership table (she is not listed among directors or named executive officers) .
- Alignment policies:
- Hedging and pledging prohibited; short sales, puts/calls, derivatives, and margin/pledging of SRRK securities are banned under the insider trading policy .
- Clawback: Compensation Recovery Policy adopted Nov 28, 2023 requires recovery of incentive-based compensation tied to financial reporting measures in the event of an accounting restatement; recovery regardless of fault (no restatements requiring recovery through 12/31/2024) .
Employment Terms
- Employment agreement, severance, and change-of-control terms for Lisa Wyman are not disclosed in the reviewed filings .
- Equity grant timing policy (company-wide): annual equity awards are granted in Q1; new hires receive awards on the second Monday of the month following start; board/committee did not time awards around MNPI in 2024 .
Investment Implications
- Execution leverage: Wyman’s mandate is explicitly tied to scaling technical and quality operations for SRRK’s evolution to a fully integrated biopharma and the anticipated first commercial launch (apitegromab) in 2025; this strengthens manufacturing/quality readiness ahead of regulatory/commercial milestones .
- Alignment and governance: Prohibitions on hedging/pledging and an adopted clawback policy support investor-aligned conduct and mitigate compensation risk, though her individual pay mix and ownership are undisclosed, limiting direct pay-for-performance assessment .
- Retention risk: Lack of disclosed employment/severance terms for Wyman creates limited visibility on retention incentives; however, her senior operator background across Generate/Acceleron and stated role centrality to commercialization imply high strategic importance to SRRK’s 2025 launch plan .
- Trading signals: No Form 4 data were identified in the reviewed documents; with no disclosed individual grants/ownership, near-term insider selling pressure assessment specific to Wyman is not possible from these filings. Company-wide equity grant timing and no-hedging/pledging policy reduce opportunistic trading risks .
Company Performance Context (TSR and Net Income)
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total Shareholder Return – $100 initial value | $36.43 | $75.68 | $173.99 |
| Net Income (USD millions) | -$135 | -$166 | -$246 |
Note: SRRK disclosed no revenue in 2023–2024; revenue in 2022 was collaboration-related .
Key Policies Relevant to Incentives and Risk
- Annual bonus framework (2024 NEOs): CEO payout based 100% on corporate goals; other NEOs 85% corporate/15% individual .
- Long-term incentives: mix of time-based options and RSUs for executives; ongoing evaluation of performance-based equity .
- No hedging/pledging; expansive clawback compliant with Nasdaq rules .
- Equity grant timing controls to avoid MNPI timing .
Role Fit to Strategy
- The CTQO role was created to fortify readiness for first expected drug approval/launch and to expand technical/quality operations for pipeline programs, indicating management focus on CMC, GMP quality, and supply chain scale-up as near-term value drivers .